⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7688794 | 0.74 | FAAH (0.40) | — | |
| SCHEMBL17508953 | 0.72 | ZDHHC20 (0.37) | — | |
| SCHEMBL16654852 | 0.67 | — | — | |
| SCHEMBL170586 | 0.67 | SMN1; SMN2 (0.32) | — | |
| Hydrochloric Acid SCHEMBL28784380 | 0.65 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL10905933 | 0.65 | CYP1A2 (0.44) | — | |
| SCHEMBL24832 | 0.64 | — | — | |
| SCHEMBL8674277 | 0.64 | TSHR (0.32) | — | |
| SCHEMBL8656915 | 0.64 | — | — | |
| SCHEMBL17226154 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260038-B1 | PURINE DERIVATIVES AS A3 ADENOSINE RECEPTOR-SELECTIVE AGONISTS | US HEALTH (US) | 2014-12-03 | — | — | EP | claimed |
| EP-2260038-A1 | PURINE DERIVATIVES AS A3 RECEPTOR- SELECTIVE AGONISTS | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (US) | 2010-12-15 | — | — | EP | claimed |
| WO-2009152431-A1 | P2Y1 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-12-17 | — | — | WO | claimed |
| WO-2009123881-A1 | PURINE DERIVATIVES AS A3 RECEPTOR- SELECTIVE AGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-10-08 | — | — | WO | claimed |
| EP-0533243-B1 | Hydantoin and succinimide-substituted spiroindanylcamphorsulfonyl derivatives | MERCK & CO INC (US) | 1997-12-17 | — | — | EP | claimed |
| US-20240170732-A1 | MIXED POLYHALIDE ELECTROLYTES FOR A STATIC BATTERY AND A METHOD FOR FABRICATING A STATIC BATTERY CELL | EOS Energy Technology Holdings, LLC (US) | 2024-05-23 | — | — | US | disclosed |
| WO-2024097835-A1 | MIXED POLYHALIDE ELECTROLYTES FOR A STATIC BATTERY AND A METHOD FOR FABRICATING A STATIC BATTERY CELL | EOS Energy Technology Holdings, LLC (US) | 2024-05-10 | — | — | WO | disclosed |
| US-11942606-B2 | Electrolyte for rechargeable electrochemical cell | EOS Energy Technology Holdings, LLC (US) | 2024-03-26 | — | — | US | disclosed |
| EP-3204977-B1 | ELECTROLYTE FOR RECHARGEABLE ELECTROCHEMICAL CELL | EOS ENERGY TECH HOLDINGS LLC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230107407-A1 | NON-HALIDE ZINC ADDITIVES FOR A SECONDARY ZINC HALIDE BATTERY | EOS Energy Technology Holdings, LLC (US) | 2023-04-06 | — | — | US | disclosed |
| US-20210119265-A1 | ELECTROLYTE FOR RECHARGEABLE ELECTROCHEMICAL CELL | EOS ENERGY STORAGE, LLC (US) | 2021-04-22 | — | — | US | disclosed |
| US-10892524-B2 | Electrolyte for rechargeable electrochemical cell | EOS ENERGY STORAGE, LLC (US) | 2021-01-12 | — | — | US | disclosed |
| US-20060160817-A1 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED | 2006-07-20 | — | — | US | disclosed |
| WO-2006050476-A2 | PYRIMIDINE DERIVATIVES AS ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060079505-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2006023852-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |